Natera, Inc. (NASDAQ:NTRA) CFO Sells $162,693.08 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 946 shares of the firm’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $171.98, for a total transaction of $162,693.08. Following the transaction, the chief financial officer now directly owns 109,474 shares of the company’s stock, valued at $18,827,338.52. The trade was a 0.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,277,837.07.
• On Thursday, October 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $126.45, for a total value of $235,955.70.
• On Monday, October 28th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The stock was sold at an average price of $118.21, for a total value of $146,343.98.

Natera Trading Down 2.5 %

Shares of NTRA stock opened at $167.61 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a 12-month low of $62.96 and a 12-month high of $183.00. The firm has a fifty day moving average of $166.20 and a 200-day moving average of $136.07.

Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company’s revenue was up 63.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.95) earnings per share. Sell-side analysts predict that Natera, Inc. will post -1.56 EPS for the current fiscal year.

Analysts Set New Price Targets

NTRA has been the topic of a number of recent analyst reports. Robert W. Baird boosted their price target on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Piper Sandler boosted their target price on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, November 18th. The Goldman Sachs Group raised their price target on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. JPMorgan Chase & Co. increased their price objective on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Finally, Morgan Stanley boosted their target price on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. One analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $162.94.

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Chartwell Investment Partners LLC increased its holdings in Natera by 37.9% during the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after purchasing an additional 11,362 shares in the last quarter. Cerity Partners LLC increased its position in Natera by 27.0% during the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after acquiring an additional 18,316 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Natera during the 3rd quarter valued at $385,000. Everence Capital Management Inc. bought a new stake in Natera during the fourth quarter worth $573,000. Finally, First Turn Management LLC bought a new position in shares of Natera in the third quarter worth about $19,760,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.